Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.77)
# 3,648
Out of 4,829 analysts
131
Total ratings
23.89%
Success rate
-32.87%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Reiterates: Buy | $38 | $26.34 | +44.27% | 5 | May 8, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 → $20 | $3.14 | +536.94% | 9 | May 2, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $1.01 | +890.10% | 4 | May 1, 2025 | |
| UBX Unity Biotechnology | Reiterates: Buy | $4 | $0.91 | +337.59% | 8 | Apr 23, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $2.81 | +967.62% | 5 | Apr 16, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $2.19 | +356.62% | 12 | Apr 4, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $30 → $42 | $14.60 | +187.67% | 7 | Apr 2, 2025 | |
| SRZN Surrozen | Reiterates: Buy | $32 | $8.35 | +283.23% | 2 | Apr 2, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $0.83 | +1,344.74% | 4 | Apr 1, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $0.95 | +744.95% | 3 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.90 | +5.54% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.77 | -20.42% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.08 | +85.19% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $9 | $9.39 | -4.15% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.66 | +173.22% | 4 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.10 | +1,936.66% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $9.06 | +231.13% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $3.08 | +1,068.83% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $202.62 | -86.18% | 1 | Aug 22, 2023 |
LENZ Therapeutics
May 8, 2025
Reiterates: Buy
Price Target: $38
Current: $26.34
Upside: +44.27%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $28 → $20
Current: $3.14
Upside: +536.94%
Immunic
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $1.01
Upside: +890.10%
Unity Biotechnology
Apr 23, 2025
Reiterates: Buy
Price Target: $4
Current: $0.91
Upside: +337.59%
Adverum Biotechnologies
Apr 16, 2025
Reiterates: Buy
Price Target: $30
Current: $2.81
Upside: +967.62%
Aldeyra Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $10
Current: $2.19
Upside: +356.62%
Mineralys Therapeutics
Apr 2, 2025
Maintains: Buy
Price Target: $30 → $42
Current: $14.60
Upside: +187.67%
Surrozen
Apr 2, 2025
Reiterates: Buy
Price Target: $32
Current: $8.35
Upside: +283.23%
FibroBiologics
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.83
Upside: +1,344.74%
Opus Genetics
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $0.95
Upside: +744.95%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.90
Upside: +5.54%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $3.77
Upside: -20.42%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.08
Upside: +85.19%
Mar 21, 2025
Downgrades: Neutral
Price Target: $18 → $9
Current: $9.39
Upside: -4.15%
Mar 19, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $3.66
Upside: +173.22%
Mar 14, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.10
Upside: +1,936.66%
Mar 12, 2025
Reiterates: Buy
Price Target: $30
Current: $9.06
Upside: +231.13%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $3.08
Upside: +1,068.83%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $202.62
Upside: -86.18%